Heart Disease and Diabetes

 

The Practical Cardiology™ Heart Disease and Diabetes clinical resource center offers readers the latest in the field of diabetes and cardiovascular disease. With the field of cardiometabolic health becoming a focal point in the fight against cardiovascular disease, this page will host content related to the latest FDA approvals, studies, guideline update, and clinical perspectives from advisory board members.

Study Highlights Need for More Comprehensive Cardiovascular Care in Women with Diabetes

October 07, 2021

A post hoc analysis of the REWIND trial suggests women with diabetes were less likely to achieve treatment targets and receive guideline-directed medical therapies than their male counterparts.

Statin Use Associated with Increased Odds of Worsening Diabetes, Study Finds

October 05, 2021

Using data from more than 80k matched pairs of statin users and comparators, investigators from UT Southwestern Medical Center found initiation of statin therapy was associated with an increased likelihood of diabetes progression, including risk of hyperglycemia and ketoacidosis.

As Insulin Resistance Increases, So Does Stroke Risk in Patients with Diabetes

September 30, 2021

Data from a recent analysis suggests patients with diabetes with the lowest levels of insulin resistance had a 40% lower risk of stroke when compared to those with the highest levels.

Lack of Blood Pressure Decreases at Night Signal Adverse Outcomes Risk in Diabetes

September 28, 2021

Research presented at the AHA's Hypertension Scientific Sessions details the increased prevalence of cardiac autonomic neuropathy and decreased survival probability associated with a non-dipping blood pressure at night.

Diabetes Medications and Stroke Prevention, With Silvio Inzucchi, MD

September 16, 2021

After presenting at TMIOA's 5th Heart in Diabetes meeting, Silvio Inzucchi, MD, reviews current knowledge related to the effects of diabetes medications on stroke risk.

Matthew Budoff, MD: Need for Greater Uptake of Newer Medications

September 15, 2021

Matthew Budoff, MD, discusses what he views as hurdles to achieving optimal prescription of newer agents in the treatment of cardiometabolic conditions, including diabetes, heart failure, dyslipidemia, and more.

PRESERVED-HF: Dapagliflozin Reduces Symptom Burden, Physical Limitations in HFpEF

September 14, 2021

Presented at HFSA 2021, PRESERVED-HF provides evidence suggesting dapagliflozin use was associated with improvements in KCCQ symptom score and 6-minute walking distance in patients with heart failure with preserved ejection fraction.

Paul Thompson, MD: Why Cardiologists Need to Be Diabetologists

September 04, 2021

Editorial advisory board member Dr. Paul Thompson reflects on how advances in diabetes management have impacted cardiovascular medicine and why staying abreast of these advances is essential to being a cardiologist in 2021.

ESC Congress 2021 Expert Perspective: Top 5 Studies With Brett Nowlan, MD

September 02, 2021

Practical Cardiology editorial advisory board member Brett Nowlan, MD, compiled a top 5 list of studies he thought were noteworthy from ESC Congress 2021 and offers his perspective on why he chose each study.

The Future of Sotagliflozin With Deepak Bhatt, MD

August 29, 2021

Deepak Bhatt, MD, discusses a presentation he gave at ESC Congress 2021 on SGLT2, 1/2 inhibition and reflects on the potential for sotagliflozin to receive approval from the FDA based on data from SOLOIST-WHF and SCORED.